Endometrial Cancer

Furthermore, we discuss its implications in female oncology-highlighting opportunities for chemotherapy, targeted therapy, and immunotherapy-and address challenges such as inflammatory balance and a lack of direct disease-specific evidence. Finally, we propose future directions for translating PANoptosis-related mechanisms into clinical strategies for female cancers.

Finally, we present available clinical data on the therapeutic potential of ER in NENs. Understanding estrogen roles in NENs may contribute to elucidate gender differences in the course of the disease and open the way to the design of new personalized therapies.

After recurrence with peritoneal dissemination and liver metastases, she received paclitaxel plus carboplatin with temporary response, followed by pembrolizumab monotherapy after detection of MSI-high status. This case illustrates that LP therapy can achieve a favorable response in dMMR EC with MLH1 promoter methylation after pembrolizumab failure. Further studies are warranted to clarify the biology of methylated dMMR tumors, establish individualized treatment strategies, and develop practical diagnostic systems to identify MLH1 promoter methylation.

Although observed in a very limited number of cases, the recurrent identification of the V411L variant among patients with advanced disease raises hypotheses and requires validation in larger cohorts. These findings underscore the need for nuanced risk stratification that goes beyond POLE mutation status alone.

T-DXd induced clinically meaningful ORRs, with safety consistent with the known profile. Data further support T-DXd as a therapeutic option for pretreated HER2-expressing gynecologic cancers.

AI-supported quality assurance is discussed alongside essential requirements of local validation, bias mitigation, and robust governance. Rather than generating new empirical data, this review employs a cluster-informed, equity-oriented lens, applying previously validated system-level typologies to contextualize implementation gaps and support context-sensitive guideline adaptation.

Molecular subtype distribution and clinicopathology differ by ethnicity in our EC population, however, no differences in survival were identified. Geographic distance/rurality were not associated with EC treatment or outcomes.

In addition, it was confirmed that STAT3 binds to and promotes the expression of YKL‑40. These findings contribute to clarifying the pathogenesis of EC.

Currently, there is not enough evidence to tailor lymph node staging according to molecular profile. Special attention should be paid to MLH1 promoter methylated tumors due to high-risk features and poor outcomes.

Genetic and epigenetic alterations detectable in cervicovaginal swabs can accurately identify ovarian and endometrial cancers, demonstrating feasibility for non-invasive molecular triage. Incorporation of TP53 and PTEN sequencing with methylation profiling warrants further prospective investigation as a potential adjunct to upper-tract oncologic surveillance.

SG demonstrated encouraging efficacy in a pretreated population that included biologically aggressive recurrent EC. Adverse events were consistent with the known safety profile.

SB-GN is common in HG-EMC but not specific. Conversely, PM-L when strictly defined (requiring central keratinization with shadow cells) is specific for CTNNB1mut status.